Phosphorylated mTOR, eIF4E, and high expression of AKT may be potentional biomarkers in order to select the candidate HNSCC patients for mTOR inhibitor-based adjuvant therapy[71,77,80]. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.